THE FIRST EXPERIENCE OF APPLICATION OF INHIBITOR BIVALIRUDIN DIRECT TROMBIN DURING CORONARY BYPASS SURGERY UNDER CONDITIONS OF EXTRACORPOREAL CIRCULATION IN ALTAY REGIONAL CARDIOLOGIC DISPANSARY
https://doi.org/10.17802/2306-1278-2015-1-81-85
Abstract
In article key information on the mechanism of effect of direct inhibitor trombina-Bivalirudina, its difference from unfractionated heparin is stated. The main clinical trials with Bivalirudin’s use in cardiovascular surgery and own first experience of application are presented in thesis during coronary shunting with cardiopulmonary-bypass.
About the Authors
A. P. Pokutnev
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
For correspondence: Pokutnev Andrew Address: 46, Malahova st.,Barnaul, 656055, Russian Federation Tel. 8 (961) 232 23 66 E-mail: apokutnev72@mail.ru
A. G. Efremushkin
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
A. P. Kosoukhov
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
A. I. Duda
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
A. A. Efremushkina
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
O. A. Bendrikov
Altay Regional Cardiologic Dispansary, Barnaul
Russian Federation
Russian Federation
References
1. Пирогов А. Л. Гепарин-индуцированная тромбоцитопения при сердечно-сосудистых вмешательствах. Механизмы развития, диагностики и методы коррекции. Комплексные проблемы сердечно-сосудистых заболеваний. 2014; 4: 96–98. Pirоgov A. L. Heparin inducent thrombocytohenia in cardiovascular surgery. Pathogenesis, diagnostics and correction methods. Complex Issues of Cardiovascular Diseases. 2014; 4: 96–98.
2. Чарная М. А., Дементьева И. И., Морозов Ю. А., Гла¬ дышева В. Г., Исаева А. М. «Искусственная» гипокоагуляция у больных с гепарин-индуцированными тромбоцитопениями (обзор литературы). Часть 1. Кардиология и сердечнососудистая хирургия. 2013; 2: 87–89. Часть 2. Кардиология и сердечно-сосудистая хирургия. 2013; 3: 90–91. Charnaia M. A., Dementeva I. I., Morozov Iu. A., Gladysheva V. G., Isaeva A. M. Artificial hypocoagulation in with Heparin-induced thrombocytohenias (literature review). Part I. Cardiology & cardiovascular surgery. 2013; 2: 87–89. Part II. Cardiology & cardiovascular sergery. 2013; 3: 90–91.
3. Greinacher A., Warkentin T. E. Heparin-induced thrombocytopenia. N. Y: Marcel Dekker. 2004; 627.
4. Mar A. W., Dixon B., Ibrahim K., Parkin J. D. Skin necrosis following subcutaneous heparin injection. Australas. J. Dermatol. 1995; 36 (4): 201–203.
5. Warkentin T. E., Roberts T. S., Hirsch J., Kelton J. G. Heparininduced skin lesions and other unusual sequelae of the heparininduced-thrombocytopenia syndrome: a nested cohort study. Chest. 2005; 127 (5): 1857–1861.
6. Ling E., Warkentin T. E. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiology. 1998; 89 (6): 1567–1569.
7. Warkentin T. E., Kelton J. G. A 14-year study of heparininduced thrombocytopenia. Am. J. Med. 1996; 101 (5): 502–507.
8. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with low molecular weight heparin and with direct thrombin inhibitor. Circulation. 1998; 97: 251–256.
9. WarkentinT.E.CookR. J. et al. Anti-PF 4/heparin antiboby formation postorhopedic surhery thromboprophylaxis: the role of nondrug risk factor and evidence for a stoichiometrybased model of immunization. J. Thromb. Haemost. 2010; 8 (3): 505–511.
10. Montalescot G., Collet J. P., Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J. Am. Coll. Cardiol. 2000; 36: 110–1115.
11. Sciulli T. M., Mauro V. F. Pharmacology and clinical use of bivalirudin. Ann. Pharmacother. 2002 Jun; 36 (6): 1028– 1041. Review.
12. Maraganore J. M., Bourdon P., Jablonski J., Ramachandran K. L., Fenton J. W. 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors ofthrombin. Biochemistry. 1990 Jul; 31; 29 (30): 7095–7101.
13. Ганюков В. И., Протопопов А. В. Медикаментозное сопровождение чрезкожных коронарных вмешательств. Новосибирск. 2014; 19–20, 47–48, 59–61. Ganiukov V. I., Protopopov A. V. Medicamentoznoe soprovogdenie chrezkognyx koronarnyx vmeshatelstv. Novosibirsk. 2014; 19–20, 47–48, 59–61.
14. Dyke C. M., Smedira N. G., Koster A., Aronson S., Harry L., McCarthy II et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery withcardiopulmonary bypass: The EVOLUTION-ON study. The Journal of Thoracic and Cardiovascular Surgery. 131 (3): 534–539.
15. Кoster A., Dyke C. M., Aldea G. et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the СHOOSE-ON trial. Ann. Thorac. Surg. 2007; 83 (2): 572–577.
16. Smedira N. G., Dyke C. M., Koster A., Jurmann M., Bhatia D. S. et al. Anticoagulation with bivalirudin for offpump coronary arterybypass grafting: The results of the EVOLUTION-OFF study. The Journal of Thoracic and Cardiovascular Surgery. March 2006; 688–692.
17. Dyke C. M., Кoster A., Aldea G. et al. Off-pump coronary artery bypass with Bivalirudin for pacients with heparin-induced thrombocytopenia antiplatelet factor four/ heparin antibodies. Ann. Thorac. Surg. 2007; 84 (3): 836–839.
18. Riess F. C., Poetzsch B., Madlener K. et al. Recombinant hirudin as an alternative for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Thorac. Cardiovasc. Surg. 2007; 55 (4): 233–238.
19. Кoster A., Hansen R., Kuppe H. et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with previous with heparin-induced thrombocytopenia typeII6 1 year experience in 57 patients. J. Cardiothorac. Vasc. Anesth. 2000; 14 (3): 243–248.
Review
For citations:
Pokutnev A.P., Efremushkin A.G., Kosoukhov A.P., Duda A.I., Efremushkina A.A., Bendrikov O.A. THE FIRST EXPERIENCE OF APPLICATION OF INHIBITOR BIVALIRUDIN DIRECT TROMBIN DURING CORONARY BYPASS SURGERY UNDER CONDITIONS OF EXTRACORPOREAL CIRCULATION IN ALTAY REGIONAL CARDIOLOGIC DISPANSARY. Complex Issues of Cardiovascular Diseases. 2015;(1):81-85. (In Russ.) https://doi.org/10.17802/2306-1278-2015-1-81-85
Views:
784
